Psoriasis Completed Phase 1 / 2 Trials for Daclizumab (DB00111)

Also known as: Psoriasis unspecified / Psoriasis, unspecified

IndicationStatusPhase
DBCOND0013339 (Psoriasis)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00050661To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis VulgarisTreatment
NCT00050648To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis VulgarisTreatment